NEW-NAF ATAXIA RESEARCH STUDIES CURRENTLY IN PROGRESS
The following are the titles of important ataxia research studies that received grant funding from the National Ataxia Foundation for the fiscal year of 2012. A summary of the completed research studies will be published in Generations in 2013:
The following are the titles and lay summaries of important ataxia research
- David Chan, M.D., Ph.D.
Identifying proteins regulated by AFG3L2 by quantitative proteomics
- Beverly Davidson, Ph.D.
RNA interference therapy for Spinocerebellar ataxia 7 (SCA7)
- Joseph Sarsero, Ph.D.
Non-viral gene therapy for the correction of Friedreich ataxia iPS cells.
- Filippo Tempia, M.D., Ph.D.
Pilot study of the first knock-in animal model of SCA28, harboring the M666R mutation
Young Investigator Award
- Brent Fogel, M.D., Ph.D.
Diagnosis of Rare and Novel Hereditary Cerebellar Ataxias Using Next-Generation Sequencing
Post-Doc Fellowship Awards
- Fadi A. Issa, Ph.D.
The effects of SCA-13 mutations on the development and electrical activity of the Purkinje neurons
- Sukanya Karan, Ph.D.
Identification of the mutation causing progressive Purkinje cell degeneration in the Shaker rat
Young Investigator for SCA Research Awards
- Janghoo Lim, Ph.D.
Molecular pathogenesis studies of spinocerebellar ataxia type 1
- Francesca Maltecca, Ph.D.
Spinocerebellar ataxia type 28, from molecular hypothesis to preclinical treatment
- Edgardo Rodriguez, Ph.D.
Development of a mouse model for SCA6
- Sokol V. Todi, Ph.D.
Mechanisms of Neuroprotection in Spinocerebellar Ataxia Type 3
- Thorsten Schmidt, Ph.D.
Isoforms and polymorphisms of Ataxin-3 as modifiers of the pathogenesis in Spinocerebellar Ataxia Type 3
Pioneer SCA Translational Grant Awards
- Albert La Spada, M.D., Ph.D.
Development of ataxin-7 knock-down therapies to treat SCA7
- Puneet Opal, M.D., Ph.D.
Exploring the therapeutic potential of VEGF in SCA1
- Harry Orr, Ph.D.
Small Molecule Inhibitor of PKA: A Therapeutic Strategy for SCA1
- Henry Paulson, M.D., Ph.D.
Novel Cell-Based Screens for Therapeutic Compounds in SCA3